Stemcell United Ltd. stock analysis
Want to see AU:OSS full AI Analyst Report?
Stemcell United Ltd. (OSS) Share Price & Analysis
OSS Stock Chart & Stats
- Day’s Range
- AUD 0.01 - AUD 0.01
- 52-Week Range
- AUD 0.01 - AUD 0.02
- Previous Close
- AUD 0.01
- Volume
- N/A
- Average Volume (3M)
- 319.11K
- Market Cap
- AUD 3.13M
- Enterprise Value
- AUD 3.81M
- Total Cash (Recent Filing)
- AUD 259.88K
- Total Debt (Recent Filing)
- AUD 555.74K
- Price to Earnings (P/E)
- ―
- Beta
- -0.65
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound
FY2026 revenue rose to about A$3.44M from A$0.35M, indicating materially stronger commercial activity and potential product traction. If retained, this larger revenue base could improve operating leverage and provide a foundation for scaling the business over the next several quarters.
Expanded Asset Base
The increase in total assets indicates that the company expanded its recorded resource base during FY2026. Although asset growth does not resolve profitability concerns, it may provide a broader platform for supporting operations and developing commercial opportunities over the medium term.
Improved Cash Flow Trend
Free cash flow improved compared with FY2025, showing some progress in reducing the scale of cash outflows. The business remains cash-flow negative, but continued improvement could gradually reduce funding pressure and strengthen the sustainability of its operating model.
Bears Say
Unprofitable Operations
Negative gross profit and a net margin near -52% show that the company has not yet demonstrated an economically sustainable business model. Without a durable improvement in pricing, costs, or product mix, higher revenue may not translate into earnings or internally generated capital.
Negative Shareholders' Equity
Persistent negative shareholders’ equity materially weakens the balance sheet and limits financial flexibility. It can increase recapitalization risk, constrain the company’s ability to fund growth internally, and amplify the impact of further operating losses over the next several quarters.
Continued Cash Burn
Operating and free cash flow of approximately negative A$2.14M show that the business is not yet self-funding. Continued cash consumption can increase reliance on external funding, reduce strategic flexibility, and make execution of longer-term growth plans more difficult.
OSS FAQ
What was Stemcell United Ltd.’s price range in the past 12 months?
What is Stemcell United Ltd.’s market cap?
When is Stemcell United Ltd.’s upcoming earnings report date?
How were Stemcell United Ltd.’s earnings last quarter?
Is Stemcell United Ltd. overvalued?
Does Stemcell United Ltd. pay dividends?
What is Stemcell United Ltd.’s EPS estimate?
How many shares outstanding does Stemcell United Ltd. have?
What happened to Stemcell United Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Stemcell United Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Stemcell United Ltd. Stock Smart Score
Company Description
Stemcell United Ltd.
Ocean Sciences Ltd. is a plant-based biotechnology company, which engages in the business of sourcing, producing, marketing, and selling traditional medicines. The company was founded by Ian Douglas Christiansen on July 25, 1984 and is headquartered in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Matthew Leonard
- Employees
- 31
- Website
- bphglobal.com
- Address
- 365 Little Collins Street, Melbourne, VIC, 3000, AU
Stemcell United Ltd. (OSS) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 3 | 5 |
| Technical Analysis | 5 | 3 | 1 |
| Moving Averages | 2 | 0 | 4 |








